Sign up to save your podcasts
Or
Share [K-Startup Interview] CrossPoint Tackles Key ADC Market Issue with Fc Silencing Tech, Attracting Global Biotech Interest
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
[K-Startup Interview] CrossPoint Tackles Key ADC Market Issue with Fc Silencing Tech, Attracting Global Biotech Interest
https://en.wowtale.net/2025/06/16/231357/
This episode features an interview with CrossPoint Therapeutics, a Korean startup focused on addressing critical side effects in antibody-drug conjugates (ADCs). The company has developed "Stealth Body" technology, which aims to prevent adverse immune cell interactions caused by the Fc region of antibodies, a common issue in current ADC treatments that leads to severe organ damage. CrossPoint believes its technology surpasses existing solutions from leading biotech firms by maintaining antibody stability and half-life while completely silencing unwanted Fc interactions. The company is actively seeking investment to fund monkey studies, a crucial step towards global licensing deals with major pharmaceutical companies interested in safer and more effective ADCs.
View all episodes
By WOWTALEhttps://en.wowtale.net/2025/06/16/231357/
This episode features an interview with CrossPoint Therapeutics, a Korean startup focused on addressing critical side effects in antibody-drug conjugates (ADCs). The company has developed "Stealth Body" technology, which aims to prevent adverse immune cell interactions caused by the Fc region of antibodies, a common issue in current ADC treatments that leads to severe organ damage. CrossPoint believes its technology surpasses existing solutions from leading biotech firms by maintaining antibody stability and half-life while completely silencing unwanted Fc interactions. The company is actively seeking investment to fund monkey studies, a crucial step towards global licensing deals with major pharmaceutical companies interested in safer and more effective ADCs.